Novartis is trading at $153.08, down 4.52% in after-hours trading, with no clear negative company-specific catalyst identified.
- Regular session gained 3.74% after closing August 19, 2026, at $160.33, then reversed sharply after-hours.
- Official August 19, 2026 announcement highlighted positive cardiovascular and pipeline data for the ESC Congress but did not explain the opposite-direction move.
- Broader market was modestly higher; no confirmed earnings release, downgrade, or adverse regulatory announcement was found.